Find in Library

Cervical cancer (CC), the fourth worldwide incessant malignant neoplasia particularly in women, emerged as a serious public health problem. Metabolic syndrome (MetS) is an accumulation of different threats aspects, which could eventually cause diabetes and cardiovascular disease as co-morbidity, further contributing to mortality that is detected by central obesity, dyslipidemia, hyperglycemia, and hypertension. Accumulatively, endemic as well as research data supports the notion of MetS increasing general malignancies occurrences, further contributing to mortality rate. Nano-scale drug delivery system, provide targeted drug delivery, increases drug absorption rates, while drug decomposition and systemic adverse effects get decreased. This article has described the different metabolic syndromes playing role in cervical cancer, alongside cervical cancer nanocarriers modern therapy.